Close Menu

Amgen Layoffs

Amgen is laying off 380 people from its research and development division, reports Fierce Biotech. The layoffs will be mainly in the US, with 226 people being let go from the company's Thousand Oaks location, with others from Seattle, South San Francisco, Boston, and possibly in the UK. Fierce Biotech notes that while the layoffs represent 2 percent of the company's overall workforce, they are 6 percent of its R&D staff.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.